NCT03946020

GBR and Autogenous Bone Chips

Name: Clinical Trial NCT03946020
Creator: Universitaire Ziekenhuizen Leuven
Keywords: Bone Resorption, Guided bone regeneration with or without autologous bone, procedure, clinical trial

Bovine Derived Xenograft in Combination With Autogenous Bone Chips Versus Xenograft Alone for the Augmentation of Bony Dehiscences Around Oral Implants: a Randomized, Controlled, Split-mouth Clinical Trial

Universitaire Ziekenhuizen Leuven·ClinicalTrials.gov·procedureCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Bone Resorption
Drug/Device/Intervention: Guided bone regeneration with or without autologous bone
Study type: Interventional
Intervention type: procedure

Sponsor & location

Primary sponsor: Universitaire Ziekenhuizen Leuven

Timeline & enrollment

Phase: N/A
Start date: Jun 01, 2013
End date: Feb 01, 2019
Enrollment: 14 participants

Primary outcome

Horizontal and vertical bone augmentation

Summary

This study will be an open, prospective, split-mouth, randomised controlled clinical trial. A total of 14 patients searching for oral implant treatment and where a GBR procedure is indicated per implant treatment will be enrolled.  All patients have to fulfill all of the inclusion criteria and none of the exclusion criteria. From all patients clinical photos will be taken.  Two sites within a patient will be randomly allocated to the 'autologous bone chips and DBBM or 'DBBM particles alone' group.  The study will be 1 year follow-up study comprising 9 visits

ICD-10 classifications

OsteolysisPathological resorption of teethBone donorPostsurgical malabsorption osteoporosisPostsurgical malabsorption osteoporosis with pathological fracture

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT03946020
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT03946020 through Pure Global AI's free database. This phase not specified trial is sponsored by Universitaire Ziekenhuizen Leuven and is currently Completed. The study focuses on Bone Resorption. Target enrollment is 14 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.